Luoxin Pharmaceuticals Hits Day Low at CNY 4.40 Amid Price Pressure

Luoxin Pharmaceuticals Group Stock Co., Ltd. experienced a significant decline today, with shares dropping by 8.61% to reach an intraday low of CNY 4.40. This performance stands in contrast to the broader market, as the China Shanghai Composite index fell by 3.05% on the same day. Over the past week, Luoxin's stock has decreased by 3.04%, while its performance over the last month shows a gain of 12.06%. However, the longer-term outlook remains concerning, with a year-to-date decline of 7.08% and a substantial drop of 52.2% over the past five years. The company has struggled with profitability, reflected in a low Return on Capital Employed (ROCE) of 3.79% and a Return on Equity (ROE) of -20.21%. Despite being net-debt free, Luoxin has faced challenges in revenue growth, with net sales declining at an annual rate of 18.37% over the last five years. The stock's performance has consistently lagged behind the China Shanghai Composite, indicating ongoing difficulties in the competitive pharmaceuticals and biotechnology sector.